Achieve Life Sciences (NASDAQ: ACHV) insider transactions
In the twelve months to 10 November 2026, executives and directors of Achieve Life Sciences reported 1 open-market sale of 20,626 shares ($175,115) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 August 2026 | Stewart Richard Alistair | Director | Open-market sale | −20,626 | $8.49 | 208,249 | Form 4 |
| 18 September 2025 | Stewart Richard Alistair | Chief Executive Officer | Option exercise | +297,500 | — | 358,376 | Form 4 |
| 18 September 2025 | Stewart Richard Alistair | Chief Executive Officer | Open-market sale | −129,501 | $2.92 | 228,875 | Form 4 |
| 18 September 2025 | Oki Mark K | Chief Financial Officer | Option exercise | +168,000 | — | 178,000 | Form 4 |
| 18 September 2025 | Oki Mark K | Chief Financial Officer | Open-market sale | −50,060 | $2.92 | 127,940 | Form 4 |
| 4 September 2025 | Xinos Jaime | Chief Commercial Officer | Option exercise | +69,000 | — | 95,286 | Form 4 |
| 4 September 2025 | Xinos Jaime | Chief Commercial Officer | Open-market sale | −20,854 | $2.77 | 74,432 | Form 4 |
| 4 September 2025 | Jacobs Cindy | President & CMO | Option exercise | +110,000 | — | 143,214 | Form 4 |
| 4 September 2025 | Jacobs Cindy | President & CMO | Open-market sale | −27,629 | $2.77 | 115,585 | Form 4 |
| 4 September 2025 | King Thomas Braxton | Director | Option exercise | +455,000 | — | 455,000 | Form 4 |
| 4 September 2025 | King Thomas Braxton | Director | Open-market sale | −139,858 | $2.77 | 315,142 | Form 4 |
| 4 September 2025 | Wan Jerry | Principal Accounting Officer | Option exercise | +34,100 | — | 46,764 | Form 4 |
| 4 September 2025 | Wan Jerry | Principal Accounting Officer | Open-market sale | −14,070 | $2.77 | 32,694 | Form 4 |
| 17 March 2025 | Stewart Richard Alistair | Chieve Executive Officer | Open-market purchase | +10,000 | $2.86 | 60,876 | Form 4 |
| 17 March 2025 | Oki Mark K | Chief Financial Officer | Open-market purchase | +10,000 | $2.89 | 10,000 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Achieve Life Sciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.